Both interminable hepatitis B and hepatitis C are predominant among the 12 million Asians and Pacific Islanders living in the United States. Huge epidemiological and clinical contrasts exist between Asian Americans and the general U.S. populace, most prominently the higher rate of essential liver growth and the differential reaction to different antiviral treatments. Perinatal and youth transmission is normal for hepatitis B infection. Transmission of hepatitis C infection most likely likewise happens right on time throughout everyday life and results from nosocomial transmission and individual to-individual spread. Asian patients with perpetual hepatitis B usually have hepatitis B e antigen-negative hepatitis B with either the precore or center promoter mutant hepatitis B infection, which may require long haul antiviral viral treatment on account of high rates of backslide following treatment. Asian patients with interminable hepatitis C may have a considerably higher danger of liver tumor however a superior reaction to interferon-based treatment, both as far as supported virological reaction and diminished future frequency of liver malignancy. Understanding these distinctions will prompt enhanced nurture Asian Americans with viral hepatitis and better illness control for hepatitis B and hepatitis C for the whole U.S.